E-Poster Available

(1) Intraoperative liposomal bupivacaine is associated with improved pain, opioid use, functional, and length of stay outcomes after total knee arthroplasty: real-world evidence

(3) Clinical and health economic outcomes with and without liposomal bupivacaine in Medicare-insured patients undergoing outpatient shoulder arthroplasty

(4) Impact of liposomal bupivacaine on healthcare resource utilization and costs in patients undergoing total knee arthroplasty in real-world ambulatory surgical centers

(10) Economic impact of early vs. late initiation of atogepant for the preventive treatment of migraine

(11) Patient perspectives on health insurance design: Experiences of beneficiaries with chronic diseases

(12) Patient Perspectives on Employer-Based Health Insurance: Experiences of Employees with Chronic Diseases

(13) Implications of Wegovy® utilization in the New York State Medicaid Program

(30) Increased adoption of IL-1 pathway inhibition and the steroid-sparing paradigm shift: temporal trends in recurrent pericarditis treatment from the RESONANCE patient registry

(31) Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM

(32) Impact of switching from high- to low-sodium oxybate on ambulatory blood pressure in people with narcolepsy

(33) Economic burden associated with systemic inflammation in patients with established atherosclerotic cardiovascular disease and stage 3-4 chronic kidney disease

(37) Healthcare Costs and Delays in Treatment Escalation in Hypertension Patients in the United States: Results from the BREAKTHROUGH Real-World Study

(46) Integrating Cell and Gene Therapies into Managed Care: An Analysis of U.S. Payer Insights

(51) Economic and Clinical Impact of Dual Orexin Receptor Antagonists Versus Zolpidem in Medicare Part D Beneficiaries with Chronic Insomnia

(52) Impact of Medication Adherence on Clinical and Economic Outcomes in Multiple Sclerosis: A Scoping Review of Real-World Evidence

(56) Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study

(60) Valbenazine improves the impacts and symptoms of tardive dyskinesia: results from the phase 4 kinect-pro study

(62) Efficacy and safety of ecopipam for Tourette syndrome: results from a phase 3, randomized, double-blind, placebo-controlled withdrawal trial

(63) Employment status and care requirements among people with amyotrophic lateral sclerosis in the United States

(66) Analysis on the net costs of administering a prior authorization policy for onabotulinumtoxinA in the chronic migraine population

(68) Healthcare resource utilization and costs in patients with multiple sclerosis treated with ofatumumab vs ocrelizumab

(71) Healthcare resource use and clinical burden in narcolepsy: An analysis of the All of Us research program

(72) Treatment patterns among patients with newly diagnosed epilepsy in the United States

(74) Longitudinal assessment of treatment costs in patients with spinal muscular atrophy receiving disease-modifying therapies

(75) What aspects of treatment are important to people living with Neuromyelitis Optica Spectrum Disorder (NMOSD)? A qualitative study

(79) Prevalence and Incidence of Generalized Anxiety Disorder Among Adults in the United States

(80) Healthcare resource utilization and costs among individuals with narcolepsy and idiopathic hypersomnia in the United States

(84) Facilitators for Implementation of Pharmacist Billing for Medication Therapy Management (MTM)

(85) Efficacy and safety of fixed-dose tavapadon, an oral, once-daily, selective D1/D5 dopamine agonist for the treatment of early Parkinson’s disease

(86) Efficacy and safety of flexible-dose tavapadon, an orally administered, once-daily, selective D1/D5 dopamine agonist for the treatment of early Parkinson’s disease

(87) Efficacy and safety of tavapadon, an orally administered, once-daily, selective D1/D5 dopamine agonist, adjunctive to levodopa for treatment of Parkinson’s disease with motor fluctuations

(91) Epinephrine delivered via sublingual film (Anaphylm) elicits rapid and consistent pharmacokinetic and pharmacodynamic responses

(96) Navigating Specialty Treatment for Dermatologic Inflammatory Conditions: Patient Journey and Treatment Persistence

(97) A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe alopecia areata

(98) Real-world treatment patterns in patients with psoriasis receiving tildrakizumab compared to ustekinumab

(99) Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: 3-year results from the ALLEGRO-LT phase 3, open-label study

(105) Economic burden of moderate-to-severe chronic hand eczema in the United States: A retrospective claims analysis

(106) Budget impact analysis of tralokinumab-ldrm for moderate-to-severe atopic dermatitis in the United States

(108) Examining the Shifts in Atopic Dermatitis: A Retrospective Study of Patient Demographics and Insurance Coverage from 2018 to 2023

(117) Accelerating quality gap closure with artificial intelligence: Clinical natural language processing and large language model-driven extraction of HEDIS measures from structured and unstructured medical records

(118) Beyond Rule-Based Risk Stratification: Redefining Risk for Better Care Coordination in Managed Care Through Artificial Intelligence

(125) Cost-effectiveness of epcoritamab vs glofitamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) after at least 2 lines of therapy in the United States

(127) PDABs in Motion: Tracing the Development of State-Led Drug Cost Regulation

(131) Impact of triptan insufficient response on medication use, health care utilization, and costs: a retrospective claims study

(132) Health care resource utilization and economic burden in patients cycling through multiple triptans for migraines: a retrospective analysis

(133) Suitability of Cost-Effectiveness Thresholds for Drug Reimbursement Decision-Making in the US Market

(135) Understanding State Medicaid Spending on Prescription Drugs: A 10-State Comprehensive Analysis of Net State Medicaid Drug Spending as Part of the Total Medicaid Budget

(137) Lower total cost of care of first-line fixed-duration venetoclax + obinutuzumab vs treat-to-progression Bruton’s tyrosine kinase inhibitor regimens in patients with chronic lymphocytic leukemia in the United States: a population-based model

(141) Lipoprotein(a) and Testing Policies: A Health Plan Claims Analysis

(144) Racial Disparities associated with Total Healthcare Expenditures (THEs) in Type 2 Diabetes Mellitus (T2DM): Impact of GLP1 RAs

(147) Expected vs observed mortality rates, expressed as number needed to treat, from a Phase 3 clinical trial program of patients with hyperphagia and Prader-Willi Syndrome treated with diazoxide choline extended release (DCCR)

(148) The burden of Prader-Willi Syndrome on patients and the healthcare system: a cross-sectional examination of emergency department visits and inpatient stays in US claims

(150) Efficacy of elinzanetant in previous or never users of HT: pooled analysis

(151) Modelling Total Healthcare Cost Offsets and Treatment Costs Associated with Treating Adults with Obesity with Tirzepatide and Semaglutide in US Clinical Practice Settings

(154) The impact of vasomotor symptoms on women in the workplace in the United States of America: results of an online survey

(155) Cost-effectiveness analysis of somapacitan-beco versus somatropin in the treatment of patients with pediatric growth hormone deficiency (GHD) in the United States

(159) Comparing the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on the incidence of neuropathy in patients with type 2 diabetes

(160) Trends in Characteristics and Anti-Obesity Medication Use Among US Employees in the Era of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs)

(170) A Novel Low-dose Atropine Eye Drop Slows the Progression of Pediatric Myopia: Evidence from the STAR Study

(171) Real-World Prescription Drug Treatment Patterns in Patients with Dry Eye Disease

(172) Two-year real-world clinical outcomes in patients with diabetic macular edema treated with faricimab in the US: The FARETINA-DME study

(181) Multivariable analysis of baseline variables associated with efficacy outcomes in the ELEVATE UC clinical program

(182) Real-world economic burden of biliary atresia in infants under 1 year of age: A US claims-based analysis

(183) Impact of COVID-19 on non-COVID related treatment patterns and outcomes in patients with inflammatory bowel disease (IBD)

(185) Real-world analysis of treatment patterns and healthcare resource utilization among patients with alcohol-associated hepatitis from 2016 to 2024

(192) Real-world characteristics of patients with overactive bladder initiating vibegron or mirabegron

(193) Proton pump Inhibitors are associated with an Increased risk of mortality among patients with kidney disease: A systematic review and meta-analysis

(195) Methods for imputing race and ethnicity in real-world data: a scoping review

(198) Comparative outcomes for transgender patients: Gaps in HIV pre-exposure prophylaxis (PrEP) adoption between transgender and cisgender individuals.

(205) Income, Health and Racial Gaps Between 340B Hospitals, Child Sites, and Nearby Neighborhoods

(206) The timing and characteristics of supplemental indications for small and large molecule medicines

(214) Factors associated with variation in drug costs in states with prescription drug affordability boards

(220) Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

(221) Transfusion-related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Pacritinib Compared to Best Available Therapy Based on PERSIST-2 Trial

(222) Real-world iptacopan use among United States patients with paroxysmal nocturnal hemoglobinuria

(224) Real-world experience with efanesoctocog alfa in patients with moderate and severe hemophilia A: Final analysis of the Adelphi hemophilia wave III disease specific programmeTM

(226) Healthcare Resource Utilization and Costs Before and After Diagnosis of Idiopathic Multicentric Castleman Disease in the United States

(228) Resource utilization and economic burden amongst a cohort of patients with hemophilia without inhibitors in the United States

(229) Mitapivat treatment usage, satisfaction and adherence among adults with pyruvate kinase deficiency in the United States

(230) The economic burden of immune thrombocytopenia in the United States: insights from a systematic literature review and key evidence gaps

(231) Real-world impact on work and school among adults with pyruvate kinase deficiency in the United States

(237) Patient, Caregiver, and Physician Perspectives on the Burden of Disease in Uncontrolled Gout and its Treatment: Concept Elicitation

(243) Economic burden of allogeneic hematopoietic stem cell transplantation in severe leukocyte adhesion deficiency-I: a US database study of primary immunodeficiencies

(244) Healthcare costs associated with the care of patients with chronic inflammatory demyelinating polyneuropathy receiving immunoglobulin or neonatal fragment crystallizable receptor inhibitor therapies in the US

(246) Quantifying the productivity burden of lupus nephritis and the potential value of obinutuzumab treatment

(253) Treatment switch among United States Medicare beneficiaries with human immunodeficiency virus

(254) Antiretroviral therapy persistence among treatment-experienced people with human immunodeficiency virus and mental health disorders in the United States

(255) Antiretroviral therapy persistence following a change or restart in regimen among people with HIV

(256) Impact of Medications for Opioid Use Disorder on Infectious Disease Management

(257) Economic Burden of Liver Progression in Patients with Chronic Hepatitis B Virus Infection in the United States

(266) Dosing to effect with weekly and monthly subcutaneous buprenorphine: post-hoc analysis of a Phase 3, open-label study

(267) Post-launch adverse events reported to FDA adverse event reporting system for long-acting injectable buprenorphine

(268) Economic impact of experiential negative symptoms among patients living with schizophrenia: Medical expenditure panel survey

(269) Healthcare resource utilization and costs of schizophrenia among Medicaid beneficiaries

(270) Indirect treatment comparison of somnolence or sedation with dopamine partial agonists versus D2 receptor antagonists in major depressive disorder and schizophrenia

(275) Healthcare resource utilization and cost among commercially insured opioid use disorder patients treated with monthly injectable buprenorphine: a retrospective claims analysis

(276) Healthcare resource utilization among patients with opioid use disorder insured by Medicaid and treated with monthly injectable buprenorphine: a retrospective claims analysis

(279) The Impact of Extreme Heat on Mental Health Utilization and Prescriptions

(280) An economic model assessing costs, relapses, and antipsychotic adherence of switching Medicaid beneficiaries with schizophrenia from oral antipsychotics to once-monthly, once-every-three-months, and once-every-six-months paliperidone palmitate

(285) Preoperative depression and anxiety as predictors of persistent opioid use after orthopedic surgery: A retrospective claims-based analysis

(286) Real-world effectiveness of interleukin-6 receptor inhibitors compared to methotrexate in steroid-refractory frail patients with polymyalgia rheumatica

(288) Indirect treatment comparison of efgartigimod vs immunoglobulins in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

(289) Economic burden of macrophage activation syndrome (MAS) in patients with Still’s disease (systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD)): analysis of a US national administrative claims database

(296) Cost-effectiveness of xofigo in bone-metastatic castration-resistant prostate cancer: a markov model analysis

(298) Assessing tumor volume: a scoping review of measurement methods and clinical utility in head and neck and lung cancers

(299) Patient-reported outcomes evaluating physical functioning and symptoms in patients with pretreated human epidermal growth factor receptor 2-mutant advanced non-small cell lung cancer - results from the Beamion LUNG-1 trial

(301) Zongertinib in patients with pretreated human epidermal growth factor receptor 2-mutant advanced non–small cell lung cancer: Beamion LUNG-1

(304) Real-world analysis of healthcare resource utilization and costs among patients with high-risk non–muscle-invasive bladder cancer with papillary-only disease who are unresponsive to Bacillus Calmette-Guérin treatment using SEER-Medicare data

(305) Real-world analysis of treatment patterns and disease recurrence among patients with high-risk non–muscle-invasive bladder cancer with papillary-only disease who are unresponsive to Bacillus Calmette-Guérin therapy using SEER-Medicare data

(307) Epidemiology and diagnostic landscape for gastroesophageal adenocarcinomas with a HER2 focus

(308) A survey of healthcare decision maker (HCDM) formulary management perspectives in crowded oncologic markets: a focus on advanced non-small cell lung cancer (aNSCLC) and relapsed/refractory multiple myeloma (RRMM)

(309) Systematic Literature Review of Healthcare Resource Use (HCRU), Costs and Health-Related Quality of Life (HRQoL) for Brexucabtagene autoleucel in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) and Precursor B-cell lymphoblastic leukemia (B-ALL)

(314) Recent Real-World Treatment Patterns of Advanced Melanoma in the United States

(315) Economic burden of neutropenia among patients treated for HR+/HER2- and triple-negative metastatic breast cancer in the United States: a retrospective claims analysis

(316) Cost-effectiveness of sotorasib vs. adagrasib in KRAS G12C-mutated previously treated non-small cell lung cancer (NSCLC): An economic evaluation on Phase 3 trial results

(319) Cost-Inefficiency of High-Dose Opioids Therapy in Disease-Free Cancer Survivors: A Real-World, U.S. Payer-Perspective Decision-Tree Analysis

(320) Trends in Industry Payments to U.S. Oncologists: Insights from the 2014 –2023 CMS Open Payments Datasets

(322) Healthcare resource utilization and costs of patients with high-risk non–muscle-invasive bladder cancer with carcinoma in situ who are unresponsive to Bacillus Calmette-Guérin treatment: A real-world analysis using SEER-Medicare data

(325) Treatment patterns and disease recurrence among patients with high-risk non–muscle-invasive bladder cancer with carcinoma in situ who are unresponsive to Bacillus Calmette-Guérin treatment: A real-world analysis using SEER-Medicare data

(326) Real-world treatment patterns, costs, and burden of illness in advanced or unresectable cutaneous melanoma following discontinuation of frontline PD-1 inhibitor therapy: A claims database analysis

(327) Healthcare resource utilization (HCRU) and costs among chemotherapy-naïve patients with metastatic castration‑resistant prostate cancer (mCRPC): a real-world assessment using data from the Veterans Affairs Healthcare System (VAHCS)

(328) Healthcare resource utilization (HCRU) and costs during second-line (2L) treatment for small-cell lung cancer (SCLC)

(329) A systematic review of economic evidence of advanced or metastatic gastroesophageal adenocarcinoma

(334) Nivolumab plus Ipilimumab as a First-line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer: a Cost-per-Outcome Analysis

(343) Research Topics Addressed in Observational Claims-based Studies in Pharmacy

(344) Disruption and adaptation in inflammatory bowel disease: Impact of the COVID-19 pandemic on treatment patterns, healthcare utilization, and vaccination in the United States

(346) Real-world healthcare resource utilization and economic burden associated with idiopathic pulmonary fibrosis in commercially insured and Medicare Advantage Populations in the United States

(348) Real-world healthcare resource utilization and economic burden associated with progressive pulmonary fibrosis in commercially insured and Medicare Advantage Populations in the United States

(349) AUVI-Q (epinephrine, USP) vs. other epinephrine auto-injector prescription was associated with reduced inpatient hospitalizations for anaphylaxis in a US retrospective commercial claims analysis

(352) Transportability to the EU Population of the Efficacy of Belumosudil Versus Best Available Therapy for the Treatment of Chronic Graft-Versus-Host Disease

(353) Real world assessment of manic events among patients with bipolar I disorder treated with cariprazine versus other atypical antipsychotics

(354) Healthcare resource utilization following cariprazine initiation among medicare beneficiaries with bipolar I disorder

(355) Real-world switch rates of injectable migraine preventive therapies in patients with chronic migraine

(356) Evaluation of unmet needs and quality-of-care indicators among patients with migraine in the United States: 2021–2022

(359) Healthcare Resource Utilization in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Study Results

(360) Real-World Clinical Outcomes and Disease Management Costs among High-Risk Non-Muscle Invasive Bladder Cancer Patients Treated with Bacillus Calmette-Guérin: A SEER-Medicare Analysis

(361) Real-world demographics, clinical characteristics, and medication utilization in biopsy-confirmed primary C3 glomerulopathy: A 20-year single-center EHR cohort study

(365) Mapping the Cirrhosis Journey: Cirrhosis Etiologies and Rates, Timing, and Cost of Complications in a US claims database

(368) Comparisons of pharmacy-dispensed medications in the 2022 Medical Expenditure Panel Survey and the Healthcare Integrated Research Database

(369) Burden of anti-seizure medication titration on healthcare resource utilization and costs among patients with focal onset seizures: A physician panel-based chart review

(370) Triptans, opioids, and rescue medications use among patients with migraines Prescribed CGRP for Migraine Prophylaxis

(374) Data linkage and tokenization in action: A systematic review of North American clinical trials utilizing linkage to real world data

(375) Socioeconomic disparities in healthcare resource utilization and costs among Medicare Fee-for-Service beneficiaries with progressive pulmonary fibrosis

(376) Real-world persistence of first-line advanced therapies in patients with psoriatic arthritis

(377) Healthcare Costs and Resource Utilization in Medicaid-insured People with Overweight or Obesity and Knee Osteoarthritis in the United States: A Retrospective Database Study

(382) A claims-based analysis of the real-world economic burden of illness in patients with Sjögren’s disease in the United States

(384) Economic burden among patients with high-risk and low-to-intermediate-risk localized prostate cancer receiving radical prostatectomy in the United States

(385) Real-world treatment history and economic outcomes of CD38 antibody-based regimens in relapsed/refractory multiple myeloma in the United States

(386) Do claims data support use of CPT category II codes for real-world evidence clinical outcomes?

(387) A Propensity Score-Matched Analysis of Healthcare Utilization and Cost in Medicaid Beneficiaries with Epilepsy

(389) Healthcare Resource Utilization and Costs in Patients with Metabolic Dysfunction Associated Steatohepatitis: A Comparison Between Patients with Diagnosed MASH, Probable MASH, and Without MASH

(390) An Analysis of solid tumor oncology patients’ respiratory vaccination rates in accordance with ASCO guidelines

(392) Impact of dupilumab on healthcare resource utilization and its treatment patterns in patients with atopic dermatitis and comorbid asthma: A non-interventional study utilizing a U.S. claims database

(394) Improved outcomes in patients with multiple sclerosis initiating cladribine tablets compared with those denied health insurance coverage in the United States

(400) Patterns of Postpartum Contraceptive Use within an Academic Health Care Setting: A Descriptive Study

(405) Efficacy of Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis (Bronchiectasis) With vs Without Maintenance Use of Macrolides: An Analysis of the ASPEN Trial

(406) The Effect of Brensocatib vs Placebo on Symptom Burden in Patients With Non-Cystic Fibrosis Bronchiectasis (Bronchiectasis) With or Without On-Study Pulmonary Exacerbations: A Post-Hoc Analysis From the ASPEN Trial

(408) Reduction in Asthma Exacerbations Following Initiation of Benralizumab Among Medicare Beneficiaries: Results from the ZEPHYR-5 Study

(413) The most common comorbidities leading to a diagnosis of chronic lung allograft dysfunction (CLAD)-bronchiolitis obliterans syndrome (BOS) subsequent to lung transplant (LTx) using an open administrative claims database in the United States (US)

(419) Evaluating the Real-World Effects of Biosimilar Introduction on Stable Patients with Rheumatologic and Inflammatory Bowel Diseases: A Three-Month Post-Switch Analysis

(420) The value of medical and pharmacy integration in managing oral oncologic medications